News

The collaboration agreement between the two parties will terminate effective March 1, 2009; until that time, Bayer Schering Pharma will continue to provide continued supply of Vasovist in

Under the agreement, the parties will co-develop ACU-4429 in dry age-related macular degeneration (AMD) as well as other potential indications in North America. Upon commercialization of ACU-4429, the

The Phase III clinical trial is designed to include a 26-week efficacy treatment period, followed by a 26-week safety period. The efficacy component of the trial is a

The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the

The Phase IIb safety and efficacy study successfully met its primary endpoint of ovulation suppression, cycle control and safety, the company said. The pharmacokinetic (PK) study demonstrated estrogen

The trial, designated NCT00725881, is investigating trans sodium crocetinate (TSC) as a treatment for peripheral arterial disease (PAD) patients who experience the severe leg pain known as intermittent

The Phase II trial is a randomized repeat-dosing, open-label, multi-center study designed to evaluate the effect of intramuscular administration of SB-509 on the progression of the disease in

The test uses Roche’s real-time polymerase chain reaction technology to quantify the amount of hepatitis B virus DNA in a patient’s blood. Doctors may use viral load testing

The Phase IIa study will be conducted at veterans’s administration hospitals in Florida. The company will enroll diabetics, 18 and older, who have diabetic ulcers of the foot